Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207

Human Gene Therapy

Volumn 10, Issue 13, 1999, Pages 2237-2243

  Walker, Jonathan R ^a   McGeagh, Kevin G ^a   Sundaresan, Periasamy ^a   Jorgensen, Timothy J ^a   Rabkin, Samuel D ^a   Martuza, Robert L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER REGRESSION; CELL DEATH; CONTROLLED STUDY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; MALE; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; VIRUS REPLICATION;

ADENOCARCINOMA; ANIMALS; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033199929     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017211     Document Type: Article

References (23)

1. ADVANI, S.J., SIBLEY, G.S., SONG, P.Y., HALLAHAN, D.E., KATAOKA, Y., ROIZMAN, B., and WEICHSELBAUM, R.R. (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5, 160-165.
2. CATALONA, W.J. (1994). Management of cancer of the prostate. N. Engl. J. Med. 331, 996-1004.
3. EASTHAM, J.A., and SCARDINO, P.T. (1998). Radical prostatectomy. In Campbell's Urology. P.C. Walsh, A.B. Retik, E.D. Vaughan, and A.J. Wein, eds. (W.B. Saunders, Philadelphia, PA) pp. 2547-2564.
4. EASTHAM, J.A., CHEN, S.H., SEHGAL, I., YANG, G., TIMME, T.L., HALL, S.J., WOO, S.L., and THOMPSON, T.C. (1996). Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 7, 515-523.
5. GOTOH, A., KAO, C., KO, S., HAMADA, K., LIU, T., and CHUNG, L. (1997). Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J. Urol. 158, 636-641.
6. HALL, S.J., SANFORD, M.A., ATKINSON, G., and CHEN, S.H. (1998). Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58, 3221-3225.
7. HILL, T.J., YIRRELL, D.L., and BLYTH, W.A. (1986). Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse. J. Gen. Virol. 67, 309-320.
8. HOLM, H.H., JUUL, H., PEDERSON, J.F., HANSEN, H., and STROYER, I. (1983). Transperineal 1-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol. 130, 283-286.
9. IRIE, H., KOYAMA, H., KUBO, H., FUKUDA, A., AITA, K., KOIKE, T., YOSHIMURA, A., YOSHIDA, T., SHIGA, J., and HILL, T. (1998). Herpes simplex virus hepatitis in macrophage-depleted mice: The role of massive, apoptotic cell death in pathogenesis. J. Gen. Virol. 79, 1225-1231.
10. LANDIS, S.H., MURRAY, T., BOLDEN, S., and WINGO, P.A. (1998). Cancer statistics. Cancer J. Clin. 48, 6-29.
11. MINETA, T., RABKIN, S.D., and MARTUZA, R.L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966.
12. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
13. OH, W.K., and KANTOFF, P.W. (1998). Management of hormone refractory prostate cancer: Current standards and future prospects. J. Urol. 160, 1220-1129.
14. PORTER, A.T., LITTRUP, P., GRIGNON, D., FORMAN, J., and MONTIE, J.E. (1998). Radiotherapy and cryotherapy for prostate cancer. In Campbell's Urology. P.C. Walsh, A.B. Retik, E.D. Vaughan, and A.J. Wein, eds. (W.B. Saunders, Philadelphia, PA) pp. 2605-2626.
15. RAINOV, N.G., DOBBERSTEIN, K.U., HEIDECKE, V., DORANT, U., CHASE, M., KRAMM, C.M., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1998). Long-term survival in a rodent brain tumor model by bradykinin-enhanced intraarterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther. 5, 158-162.
16. REMBRINK, K., ROMIJN, J.C., VAN DER KWAST, T.H., RUBBEN, H., and SCHRODER, F.H. (1997). Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate 31, 168-174.
17. RODRIGUEZ, R., SCHUUR, E.R., LIM, H.Y., HENDERSON, G.A., SIMONS, J.W., and HENDERSON, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
18. STEPHENSON, R.A., DINNEY, C.P., GOHJI, K., OTDONEZ, N.G., KILLION, J.J., and FIDLER, I.J. (1992). Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 84, 951-957.
19. TILLEY, W.D., WILSON, C.M., MARCELLI, M., and McPHAUL, M.J. (1990). Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50, 5382-5386.
20. TODA, M., RABKIN, S.D., and MARTUZA, R.L. (1998a). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2177-2185.
21. TODA, M., MARTUZA, R.L., KOJIMA, H., and RABKIN, S.D. (1998b). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
22. TODA, M., RABKIN, S.D., KOJIMA, H., and MARTUZA, R.L. (1999). Herpes simplex virus as an "in situ cancer vaccine" for the induction of specific antitumor immunity. Hum. Gene Ther. 10, 385-393.
23. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.